Seeking Alpha

FDA approves Farxiga

  • The FDA approves AstraZeneca (AZN +0.3%) and Bristol-Myers Squibb's (BMY +1.2%) Farxiga (dapaglifozin).
  • The drug is intended to improve glycemic control in adults with Type 2 diabetes.
  • Farxiga isn't recommended for patients with active bladder cancer and the regulator is "requiring six post-marketing studies," including a CVOT.
  • FDA PR
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector